Kbc Group Nv Neurocrine Biosciences Inc Transaction History

Kbc Group Nv

$37 Billion
Q2 2025

A detailed history of Kbc Group Nv transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Kbc Group Nv holds 14,566 shares of NBIX stock, worth $2.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,566

Previous 13,835 5.28%

Holding current value

$2.08 Million

Previous $1.53 Million 19.61%

% of portfolio

0.0%

Previous 0.0%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 08, 2025	BUY	$87.54 - $128.18 $63,991 - $93,699	731 Added 5.28%	14,566 $1.83 Million
Q1 2025 Apr 25, 2025	SELL	$107.22 - $153.29 $53,073 - $75,878	-495 Reduced 3.45%	13,835 $1.53 Million
Q4 2024 Jan 22, 2025	SELL	$111.62 - $139.44 $518,140 - $647,280	-4,642 Reduced 24.47%	14,330 $1.96 Million
Q3 2024 Nov 06, 2024	BUY	$114.58 - $153.15 $954,680 - $1.28 Million	8,332 Added 78.31%	18,972 $2.19 Million
Q2 2024 Jul 17, 2024	BUY	$130.86 - $143.19 $19,890 - $21,764	152 Added 1.45%	10,640 $1.47 Million
Q1 2024 May 08, 2024	SELL	$130.4 - $143.74 $12,257 - $13,511	-94 Reduced 0.89%	10,488 $1.45 Million
Q4 2023 Feb 13, 2024	SELL	$106.07 - $132.76 $2.04 Million - $2.55 Million	-19,226 Reduced 64.5%	10,582 $1.39 Million
Q3 2023 Feb 15, 2024	SELL	$94.02 - $117.1 $1.19 Million - $1.49 Million	-12,685 Reduced 40.22%	18,852 $2.12 Million
Q2 2023 Feb 15, 2024	BUY	$89.53 - $104.87 $2.56 Million - $2.99 Million	28,555 Added 957.58%	31,537 $2.97 Million
Q2 2023 Jul 28, 2023	BUY	$89.53 - $104.87 $232,688 - $272,557	2,599 Added 9.55%	29,808 $2.81 Million
Q1 2023 Feb 14, 2024	SELL	$94.11 - $123.02 $76,040 - $99,400	-808 Reduced 2.79%	28,153 $2.85 Million
Q1 2023 May 04, 2023	BUY	$94.11 - $123.02 $2.29 Million - $3 Million	24,370 Added 858.4%	27,209 $2.75 Million
Q4 2022 Feb 14, 2024	BUY	$106.72 - $127.06 $2.77 Million - $3.3 Million	25,937 Added 857.71%	28,961 $3.46 Million
Q3 2022 Feb 15, 2024	SELL	$92.03 - $107.81 $699,428 - $819,356	-7,600 Reduced 71.82%	2,982 $317,000
Q2 2022 Feb 14, 2024	BUY	$75.79 - $100.07 $14,021 - $18,512	185 Added 6.52%	3,024 $295,000
Q1 2022 Feb 14, 2024	SELL	$72.45 - $94.81 $452,015 - $591,519	-6,239 Reduced 68.73%	2,839 $266,000
Q1 2022 May 06, 2022	SELL	$72.45 - $94.81 $452,015 - $591,519	-6,239 Reduced 68.73%	2,839 $266,000
Q4 2021 Feb 14, 2024	SELL	$79.65 - $106.22 $119,793 - $159,754	-1,504 Reduced 14.21%	9,078 $773,000
Q4 2021 Feb 03, 2022	SELL	$79.65 - $106.22 $247,153 - $329,600	-3,103 Reduced 25.47%	9,078 $773,000
Q2 2020 Aug 10, 2020	BUY	$85.09 - $130.36 $600,224 - $919,559	7,054 Added 137.59%	12,181 $1.49 Million
Q4 2019 Feb 11, 2020	BUY	$86.8 - $118.57 $445,023 - $607,908	5,127 New	5,127 $551,000
Q3 2019 Nov 07, 2019	SELL	$83.82 - $101.5 $9,220 - $11,165	-110 Closed	0 $0
Q2 2019 Dec 03, 2019	BUY	$72.24 - $91.27 $7,946 - $10,039	110 New	110 $10,000
Q2 2019 Jul 30, 2019	SELL	$72.24 - $91.27 $7,946 - $10,039	-110 Closed	0 $0
Q1 2019 Dec 03, 2019	BUY	$69.31 - $91.53 $7,624 - $10,068	110 New	110 $10,000
Q1 2019 May 10, 2019	SELL	$69.31 - $91.53 $7,624 - $10,068	-110 Closed	0 $0
Q4 2018 Dec 03, 2019	BUY	$68.32 - $124.36 $7,515 - $13,679	110 New	110 $8,000
Q4 2018 Jan 31, 2019	SELL	$68.32 - $124.36 $7,515 - $13,679	-110 Closed	0 $0
Q3 2018 Dec 03, 2019	BUY	$98.88 - $125.85 $10,876 - $13,843	110 New	110 $14,000
Q3 2018 Nov 14, 2018	SELL	$98.88 - $125.85 $10,876 - $13,843	-110 Closed	0 $0
Q2 2018 Dec 03, 2019	BUY	$75.3 - $105.99 $8,283 - $11,658	110 New	110 $11,000
Q2 2018 Aug 03, 2018	SELL	$75.3 - $105.99 $8,283 - $11,658	-110 Closed	0 $0
Q1 2018 Dec 03, 2019	BUY	$75.88 - $92.43 $8,346 - $10,167	110 New	110 $9,000

Others Institutions Holding NBIX

# of Institutions

661

Shares Held

102M

Call Options Held

290K

Put Options Held

214K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.6B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.

Account